Skip to content

Xencor XNCR Net Income

Net Income at other companies

Amgen logo
AmgenAMGN
$1.82B+5.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$24.36M-3.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$43.17M+5.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.88M-34.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$102.3M-57.3%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's net income?
Xencor (XNCR) reported net income of -$128.92M in Q1 2026.
How has Xencor's net income changed year-over-year?
Xencor's net income decreased by 166.3% year-over-year, from -$48.42M to -$128.92M.
What is the long-term trend for Xencor's net income?
Over 4 years (2021 to 2025), Xencor's net income has grown at a 2.7% compound annual growth rate (CAGR), from $82.63M to -$91.92M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.